

Entreprise de fabrication de produits pharmaceutiques de la région MENA âgée de 40 ans



MERGERSCORP

Entreprise de fabrication de produits pharmaceutiques de la région MENA âgée de 40 ans

Cette entreprise de fabrication de produits pharmaceutiques a été fondée il y a environ 40 ans à Amman, en Jordanie. Elle détient la référence régionale en matière d'innovation avec plus de 70 brevets.

Grâce à cette innovation, les activités ont été diversifiées en dehors de l'industrie pharmaceutique générique traditionnelle, par la filialisation de plates-formes technologiques matures dans des filiales dotées d'une gestion et de ressources indépendantes.

Verticales

1. Activité principale de produits pharmaceutiques génériques de marque.
2. Les produits naturels à travers la filiale.
3. Diagnostics biotechnologiques par l'intermédiaire de la filiale.
4. Nouveaux excipients et systèmes d'administration de médicaments par l'intermédiaire de la filiale.

Produits

Les produits couvrent un large éventail de catégories thérapeutiques, notamment les systèmes cardiovasculaire, gastro-intestinal, nerveux central, anti-infectieux, endocrinien, musculo-squelettique, respiratoire, obstétrique, gynécologique et urinaire, et immunitaire.

Entreprises pharmaceutiques

Elle propose plus de 200 produits pharmaceutiques qui répondent aux besoins des consommateurs et des professionnels de la santé. Ces produits comprennent des comprimés, des gélules, des suppositoires, des sirops et des suspensions, qui sont fabriqués conformément aux bonnes pratiques de fabrication (BPF). L'entreprise dispose d'un avantage concurrentiel qui en fait l'un des principaux laboratoires pharmaceutiques, car ses produits sont de grande "qualité".

Produits naturels

Elle est reconnue comme l'une des meilleures entreprises du Moyen-Orient spécialisée dans le développement et la production de produits médicaux à base de plantes et d'herbes à partir d'extraits de plantes médicinales normalisés, offrant plus de 50 produits innovants naturels et à base d'herbes avec des opérations commerciales dans plus de 20 pays à travers le monde.

Biotechnologie

Il s'agit d'un développeur et d'un producteur de produits de santé biotechnologiques exclusifs, spécialisé dans la production.

TARGET PRICE

\$45,000,000

GROSS REVENUE

\$37,000,000

EBITDA

\$6,279,944

BUSINESS TYPE

Pharmaceutique

COUNTRY

Jordanie

BUSINESS ID

L#20230509

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

MERGERSCORP

WWW.MERGERSCORP.COM